Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod induction therapy in moderately to severely active Crohn's disease
2019-002895-14Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in Crohn's disease (3 arms), sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Endoscopic response at Week 14. Started Dec 2019; status: terminated.
02
Drugs
etrasimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-002895-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002895-14.